

## DAFTAR PUSTAKA

- Adel, N. (2017). Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. *The American Journal of Managed Care*. 10(2), 310–321.
- Albano DF., Fausto RA., Maurizio T., Rena DA., Enzo B., Basurto C., *et al.* (1995). Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis: *Annals of Oncology*. 8 (6), 805-10.
- Al Qadire, M. (2018) Chemotherapy-Induced Nausea and Vomiting: Incidence and Management in Jordan. *Clinical Nursing Research*. 5(4), 315–22.
- Arfiani, R. F., Susilo, D. H. dan Suprpti, B. (2017). Comparison of the Antiemetic Effectiveness Between Granisetron and Dexamethasone With Ondansetron and Dexamethasone in Acute-Phase Chemotherapy Patients. *Folia Medica Indonesiana*, 52(3), 185.
- Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. (2018). Cancer of the ovary, fallopian tube, and peritoneum. *International Journal of Gynecology and Obstetrics*, 143, 59–78.
- Booth, C., Clemons, M., Dranitsaris, G., A. J.-T. (2007). Chemotherapy-induced nausea and vomiting in breast cancer patients: A prospective observational study. *Europepmc*, 10(1), 19–28.
- Bouganim, N., Dranitsaris, G., Hopkins, S., Vandermeer, L., Godbout, L., Dent, S., *et al.* (2012). Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. *Current Oncology*. 9(6), 414–421.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*. 68(6):394-424.
- CNI, N. C. I. (2019). NCI Dictionary of Cancer Terms. National Cancer Institute.
- Colombo, N., Sessa, C., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., *et al.* (2019). ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. *Annals of Oncology*, 9 (1-18).

- Universitas Gadjah Mada, 2021 | Diunduh dari <http://etd.repository.ugm.ac.id/>
- Davidson, W., Teleni, L., Muller, J., Ferguson, M., McCarthy, A. L., Vick, J., & Isenring, E. (2012). Malnutrition and chemotherapy-induced nausea and vomiting: Implications for practice. *Oncology Nursing Forum*. <https://doi.org/10.1188/12.ONF.E340-E345>
- Fabi, A., Barduagni, M., Lauro, S., Portalone, L., Mauri, M., De Marinis, F., Cognetti, F. (2003). Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? *Supportive Care in Cancer*, 11(3), 156–161.
- Gisev N, Bell JS, Chen TF. (2013). Interrater agreement and interrater reliability: key concepts, approaches, and applications. *Res Soc Adm Pharm*, 9(3), 330–8.
- Goi, T., Nakazawa, T., Kimura, Y., K. S.-J. P. C. (2012). Retrospective analysis of chemotherapy-induced nausea and vomiting (CINV) in colorectal cancer patients treated with antiemetics. *Semanticscholar*, 11(2), 110–8.
- Gupta, K., Walton, R., & Kataria, S. P. (2021). Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends. *Cancer treatment and research communications*, 26, 100278.
- Hamadani, M., Chaudhary, L., Awan, F. T., Khan, J. K., Kojouri, K., Ozer, H., *et al.* (2007). Management of platinum-based chemotherapy-induced acute nausea and vomiting: Is there a superior serotonin receptor antagonist?, *Journal of Oncology Pharmacy Practice*, 13(2), 69–75.
- Hawkins, R. dan Grunberg, S. (2009). Chemotherapy-induced nausea and vomiting: Challenges and opportunities for improved patient outcomes,” *Clinical Journal of Oncology Nursing*, 12, 1-18
- Hesketh, P. J. (2008). Chemotherapy-Induced Nausea and Vomiting. *New England Journal of Medicine*, 358(23), 2482–2494.
- Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y, Clark-Snow, R. A, *et al.* (2017). Antiemetics: American Society of Clinical Oncology clinical practice guideline update. *Journal of Clinical Oncology*, 35(28), 3240–3261.
- Horn CC, Wallisch WJ, Homanics GE, Williams JP. (2014). Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting. *Eur. J. Pharmacol.* 722(1), 55–66.
- Jordan, K., Sippel, C. and Schmoll, H. (2007). Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations. *The Oncologist*. 14, 1-10

Kawazoe, H., Murakami, A., Yamashita, M., K. N.-C. (2018). Patient-related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-based Chemotherapy. *Elsevier*. Retrieved from

[https://www.sciencedirect.com/science/article/pii/S0149291818304958?casa\\_token=Muxdq0A91t8AAAAA:h4rVwE\\_go13s0JI8r16heGzGd\\_oaLXs3weeFTDV73AkgLKZO6KNvsWsTGhXn3poP48e5r9upGrV2](https://www.sciencedirect.com/science/article/pii/S0149291818304958?casa_token=Muxdq0A91t8AAAAA:h4rVwE_go13s0JI8r16heGzGd_oaLXs3weeFTDV73AkgLKZO6KNvsWsTGhXn3poP48e5r9upGrV2)

Kris, M. G., Urba, S. G. dan Schwartzberg, L. S. (2011). Clinical roundtable monograph. Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion. *Clinical advances in hematology & oncology: H&O*, 9(1), 1–15

Jakobsen, J. N., & Herrstedt, J. (2009). Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients. *Critical Reviews in Oncology/Hematology*. <https://doi.org/10.1016/j.critrevonc.2008.12.006>

Janelins, M. C., Tejani, M. A., Kamen, C., Peoples, A. R., Mustian, K. M., & Morrow, G. R. (2013). Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. *Expert Opinion on Pharmacotherapy*. <https://doi.org/10.1517/14656566.2013.776541>

Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., Sessa, C. *et al.* (2013). Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 4 Suppl 6, vi24–vi32.mdoi: 10.1093/annonc/mdt333.

Lohr, L. (2008). Chemotherapy-induced nausea and vomiting. *Cancer Journal*. doi: 10.1097/PPO.0b013e31816a0f07.

Mahesh, R., Perumal, R. V., & Pandi, P. V. (2004). Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods. In *ingentaconnect.com*. Retrieved from <https://www.ingentaconnect.com/content/govi/pharmaz/2005/00000060/000002/art00001>

MASCC. (2017). Quick Start Guide to the MASCC Antiemesis Tool (MAT). [Www.Mascc.Org](http://www.mascc.org).

MASCC/ISOO 2017 Annual Meeting. (2017). Supportive care in cancer :official journal of the Multinational Association of Supportive Care in Cancer. doi: 10.1007/s00520-017-3704-x.

Molassiotis, A. et al. (2007). Validation and Psychometric Assessment of a Short Clinical Scale to Measure Chemotherapy-Induced Nausea and Vomiting: The

Universitas Gadjah Mada, 2021. | Diunduh dari <http://etd.repository.ugm.ac.id/>  
MASCC Antiemesis Tool. Journal of Pain and Symptom Management. doi:  
10.1016/j.jpainsymman.2006.10.018.

Molassiotis, A., Lee, P., Burke, T., M. D.-J (2016). Anticipatory nausea, risk factors, and its impact on chemotherapy-induced nausea and vomiting: results from the Pan European Emesis Registry study. *Elsevier*. Retrieved from <https://www.sciencedirect.com/science/article/pii/S0885392416000579>

Mosa, A. S. M., Hossain, A. M., Lavoie, B. J., & Yoo, I. (2020). Patient-Related Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review. *Frontiers in Pharmacology*, 11. <https://doi.org/10.3389/fphar.2020.00329>

Muhire, I. (2016). Efficacy and Tolerability of Granisetron Versus Ondansetron in the Prevention of Chemotherapy Induced Nausea and Vomiting Among Cancer Patients at Kenyatta.

National center for Biotechnology Information. Ondansetron. PubChem Compound Database. <https://pubchem.ncbi.nlm.nih.gov/compound/Ondansetron> diakses Maret 2020

National center for Biotechnology Information. Granisetron. PubChem Compound Database. <https://pubchem.ncbi.nlm.nih.gov/compound/Granisetron> diakses Maret 2020

Navari RM. (2013). Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. *Drugs* 73(3), 249–262.

Petrella, T., Clemons, M., Joy, A., Young, S., Oncol, W. C.-J. S. (2009). *Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical validated prediction tool*.

Sastroasmoro, S., (2011). Perkiraan Besar Sampel dalam Penelitian Klinis, Dasar-dasar Metodologi Penelitian.

Shankar, A., Roy, S., Malik, A., Julka, P. K., Rath, G. K. (2015). Prevention of chemotherapy-induced nausea and vomiting in cancer patients. *Asian Pacific Journal of Cancer Prevention*. <https://doi.org/10.7314/APJCP.2015.16.15.6207>

Schwartzberg, L. S. (2006). Chemotherapy-induced nausea and vomiting: State of the art in 2006. *Journal of Supportive Oncology*.

Tanioka, M., Kitao, A., Matsumoto, K., cancer, N. S. (2013). Placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years

- Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., *et al.* (2018). Ovarian cancer statistics. *CA: A Cancer Journal for Clinicians*. 68(4), 284–294. doi: 10.3322/caac.21456.
- Trammel M, Roederer M, Patel J, McLeod H. (2013). Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? *Curr. Oncol. Rep.* 15(3), 276–285.
- Vrabel, M. (2007). Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials. *Clinical journal of oncology nursing*. doi: 10.1188/07.CJON.809-813.
- Widagdo, R., Dr. Heru Pradjatmo, M. K. S. (2009). *Angka harapan hidup penderita kanker ovarium Rumah Sakit Sardjito*.
- Yahata, H., Kobayashi, H., Sonoda, K., Shimokawa, M., Ohgami, T., Saito, T., *et al.* (2016). Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. *International Journal of Clinical Oncology*, 21(3), 491–497. doi: 10.1007/s10147-015-0928-y.